Optherion has offices and laboratories in New Haven, CT., and on the biotechnology campus of the University of Iowa in Coralville, IA.
Optherion, Inc. is an early-stage biotechnology company that is developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on recent scientific discoveries linking certain genes to AMD. Optherion has offices and laboratories in New Haven, CT., and on the biotechnology campus of the University of Iowa in Coralville, IA.
About the Investors:
Additional information about the investors is available on their websites: Quaker BioVentures, Philadelphia, http://www.quakerbio.com; Domain Associates, Princeton, NJ and San Diego, http://www.domainvc.com; Johnson & Johnson Development Corporation, New Brunswick, NJ, http://www.jjdevcorp.com; Purdue Pharmaceutical Products L.P., Stamford, CT, http://www.purduepharma.com; Pappas Ventures, Research Triangle Park, NC, http://www.pappasventures.com; Biogen Idec New Ventures, Cambridge, MA, http://www.biogenidec.com/site/newventures.html; and GE Healthcare Financial Services, Chicago, IL, http://www.gehealthcarefinance.com.
|SOURCE Optherion, Inc.|
Copyright©2007 PR Newswire.
All rights reserved